Gilead and Arcus announce results from colorectal cancer treatment trial

Betsy Goodfellow | June 3, 2024 | News story | Research and Development Arcus, Gilead, Oncology, clinical trial, colorectal cancer 

Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims to assess the safety and efficacy of etrumadenant plus zimberelimab, FOLFOX chemotherapy and bevacizumab (EZFB) in the treatment of third-line metastatic colorectal cancer (mCRC).

The full results are expected to be announced at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

This cohort of the trial included 112 patients, and demonstrated a median overall survival (OS) of 19.7 months for those treated with EZFB compared to only 9.5 months for those treated with regorafenib, as well as a median progression-free survival of 6.2 months with EZFB compared to 2.1 months on regorafenib.

Dr Zev A Wainberg MD MSc, co-director of the GI Oncology programme at the Universiyt of California Los Angeles, US, and a principal investigator on the trial, commented: “ARC-9 is the first randomised phase 2 study to show that combining an adenosine receptor blocker with anti-PD-1, anti-VEGF and chemotherapy can meaningfully improve clinical outcomes for people with metastatic colorectal cancer who have progressed on at least two prior therapies. 19.7 months is the longest median overall survival reported in third-line mCRC and warrants further investigation of an etrumadenant-based regimen as a potential treatment option in CRC.”

Betsy Goodfellow

Related Content

Takeda shares data from phase 3 trial of CIPD treatment

Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety …

First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment

Assembly Biosciences has announced that the first participant has been dosed in its phase 1b …

Innate Pharma shares results from phase 1/2 trial for blood cancer treatment

Innate Pharma has announced updated efficacy and safety results from the dose-escalation part of the …

Latest content